Simulations Plus and the University of Bath Awarded New FDA Grant - Seite 2

FDA scientific and program staff will actively collaborate with the University of Bath, Colorado School of Mines, University of Reading, and Simulations Plus. Dr. Le Merdy, with assistance from Dr. Jessica Spires and Dr. Jasmina Novakovic at Simulations Plus, will coordinate modeling and simulation activities of the contract.

“By combining our expertise with Simulations Plus’ cutting-edge research, we are charting a course towards more efficient drug development and safer healthcare solutions. The project will be a great way for both industry and academia to make that leap from research into real life applications, with potential benefits of tangible patient outcomes,” added Dr. Delgado-Charro. “Our primary objective is to enable the creation of innovative models that bridge the divide between in vitro and in vivo data. The comprehensive framework and best practices established through this contract will hold significant value for both the FDA and the companies involved in developing topical formulations.”

Funding for this collaboration is made possible by the Food and Drug Administration through grant award 1U01FD007957-01. Views expressed in this press release do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.

About the Delgado-Charro laboratory in the Department of Life Sciences at the University of Bath

Professor Delgado-Charro’s laboratory focuses on transdermal and topical drug delivery, development of optimized methods to treat nail diseases such as onychomycosis and psoriasis, non-invasive sampling for drug monitoring and pharmacokinetics, and mathematical modeling to predict the accumulation and absorption of chemicals in and across the skin. Her research has been funded by esteemed organizations including the Leo Foundation, the UK Engineering and Physics Research Council, EPSRC, Parkinson’s Disease Society UK, the UK Medical Research Council, the Swiss National Foundation, the NHS-NIC, the U.S. FDA and several pharmaceutical companies. Professor Delgado-Charro has published 123 peer-reviewed articles in highly respected journals in the pharmaceutics and chemicals fields as well as 11 book chapters.